The challenge of managing drug interactions in elderly people

L Mallet, A Spinewine, A Huang - The Lancet, 2007 - thelancet.com
Drug therapy is essential when caring for elderly patients, but clearly it is a double-edged
sword. Elderly patients are at high risk of having drug interactions, but the prevalence of …

Cell delivery of therapeutic nanoparticles

JE McMillan, E Batrakova, HE Gendelman - Progress in molecular biology …, 2011 - Elsevier
Nanomedicine seeks to manufacture drugs and other biologically relevant molecules that
are packaged into nanoscale systems for improved delivery. This includes known drugs …

A simple and robust method for connecting small-molecule drugs using gene-expression signatures

SD Zhang, TW Gant - BMC bioinformatics, 2008 - Springer
Background Interaction of a drug or chemical with a biological system can result in a gene-
expression profile or signature characteristic of the event. Using a suitably robust algorithm …

[图书][B] Clinical toxicology: principles and mechanisms

FA Barile - 2003 - taylorfrancis.com
Concise and authoritative, Clinical Toxicology: Principles and Mechanisms examines the
complex interactions associated with clinical toxicological events and chemical exposure or …

Patient counseling about herbal-drug interactions

S Hussain - African Journal of Traditional, Complementary and …, 2011 - ajol.info
Many people have the mistaken notion that, being natural, all herbs and foods are safe; this
is not so. Very often, herbs and food may interact with medications you normally take, result …

A review on dynamics of permeability-glycoprotein in efflux of chemotherapeutic drugs

P Rani, P Mandal, BK Rajak, DV Singh - Frontiers in Drug Discovery, 2024 - frontiersin.org
Permeability-glycoprotein (P-gp) belongs to the ABS transporter protein family, with a high
expression rate in cancerous cells. The substrate/inhibitors of the protein are structurally …

A high-throughput U-HPLC–MS/MS assay for the quantification of mycophenolic acid and its major metabolites mycophenolic acid glucuronide and mycophenolic acid …

J Klepacki, J Klawitter, J Bendrick-Peart… - … of Chromatography B, 2012 - Elsevier
Mycophenolic acid (MPA) is used as an immunosuppressant after organ transplantation and
for the treatment of immune diseases. There is increasing evidence that therapeutic drug …

Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases

KC Meyer, C Decker… - Clinics in chest …, 2010 - chestmed.theclinics.com
In addition to the extrapulmonary disease manifestations and nonpulmonary organ system
dysfunction patterns that characterize specific forms of connective tissue disease (CTD) …

The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation

N Picard, P Marquet - Expert opinion on drug metabolism & …, 2011 - Taylor & Francis
Introduction: Immunosuppressive drugs have a narrow therapeutic range and large inter-
individual response variability. This has prompted pharmacogenetic studies, mostly with …

Association between elevated whole blood Epstein–Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft …

VN Ahya, LP Douglas, C Andreadis, S Arnoldi… - The Journal of heart and …, 2007 - Elsevier
BACKGROUND: Accurate functional assessment of patient immunosuppression after solid-
organ transplantation remains elusive. Despite therapeutic serum immunosuppressive drug …